2023 World Conference on Lung Cancer (Posters)-P2.09. FURVENT, Phase 3 Trial Testing Furmonertinib vs Chemotherapy as First-Line Treatment for Advanced NSCLC with EGFR exon 20 Insertions

P2.09. FURVENT, Phase 3 Trial Testing Furmonertinib vs Chemotherapy as First-Line Treatment for Advanced NSCLC with EGFR exon 20 Insertions - PDF(Slides)

Back to course

Pdf Summary

The FURVENT trial is a global, phase 3 study that aims to evaluate the effectiveness and safety of furmonertinib compared to chemotherapy as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations. Furmonertinib is an oral medication that specifically targets EGFR mutations, including the rare EGFR exon 20 insertion mutations.<br /><br />The trial is enrolling 375 patients who will be randomly assigned to receive either furmonertinib at a dose of 160 mg or 240 mg, or platinum-based chemotherapy. The chemotherapy regimen includes cisplatin or carboplatin plus pemetrexed for four cycles, followed by pemetrexed maintenance therapy. The primary endpoint of the study is progression-free survival (PFS), which will be assessed by blinded independent central review. Secondary endpoints include overall survival, investigator-assessed PFS, objective response rate, and duration of response.<br /><br />Preliminary data from the FAVOUR study, which evaluated furmonertinib as a first-line treatment for NSCLC patients with EGFR exon 20 insertion mutations, showed a promising overall response rate of 70% with well-tolerated safety at a daily dose of 240 mg. The updated data from the FAVOUR study will be presented at the World Conference on Lung Cancer (WCLC) in 2023.<br /><br />The FURVENT trial is funded by ArriVent Biopharmaceuticals and Shanghai Allist Pharmaceuticals Inc. Patients enrolled in the study must have locally advanced or metastatic non-squamous NSCLC that is not amenable to curative surgery or radiotherapy. The trial has specific inclusion and exclusion criteria and is ongoing for enrollment.<br /><br />The primary comparison will be between the two furmonertinib treatment arms and the chemotherapy arm using a stratified log-rank test for PFS. Overall survival will also be analyzed similarly to the PFS endpoint.<br /><br />This trial aims to provide valuable information on the efficacy and safety of furmonertinib as a first-line treatment option for NSCLC patients with EGFR exon 20 insertion mutations, potentially offering a targeted therapy alternative to standard chemotherapy.

Asset Subtitle

Alexander Spira

Meta Tag

Speaker Alexander Spira

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

FURVENT trial

furmonertinib

chemotherapy

NSCLC

EGFR exon 20 insertion mutations

progression-free survival

overall survival

FAVOUR study

WCLC

targeted therapy alternative